AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15540740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 8113
Study 15540740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8113
Study 11422108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 100 mg/day
Number of subjects: 227
Study 11422108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 50 mg/day
Number of subjects: 227
Study 11422108 — intervention group
Group type: COMPARATOR
Intervention: Transdermal testosterone patches (5 mg T/day)
Number of subjects: 227
Study 9231954 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly phone calls to uncover problems and encourage use
Number of subjects: 33
Study 9231954 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information about sleep apnea and importance of regular CPAP use
Number of subjects: 33
Study 9231954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study 8193888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral-acquisition computed tomography (SACT)
Number of subjects: 104
Study 8193888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral-acquisition computed tomography (SACT) with pitch greater than 1.0
Number of subjects: 104
Study 8193888 — intervention group
Group type: COMPARATOR
Intervention: Conventional computed tomography (CCT)
Number of subjects: 104
Study 2902681 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg zaltidine once daily for 4 weeks
Number of subjects: 135
Study 2902681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 31742670 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 344
Study 31742670 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation plus standard CDC print materials
Number of subjects: 344
Study 31742670 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation plus culturally targeted print materials
Number of subjects: 344
Study 31742670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 344
Study 30615248 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training in hypoxia (AitH; FiO2 = 17.2%; n = 13)
Number of subjects: 59
Study 30615248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval training in hypoxia (SitH; FiO2 = 17.2%; n = 15)
Number of subjects: 59
Study 30615248 — intervention group
Group type: COMPARATOR
Intervention: Aerobic interval training in normoxia (AitN; n = 15)
Number of subjects: 59
Study 30615248 — intervention group
Group type: COMPARATOR
Intervention: Sprint interval training in normoxia (SitN; n = 18)
Number of subjects: 59
Study 28645949 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g/day S. maxima intake
Number of subjects: 80
Study 28645949 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical systematic exercise programme at moderate intensity
Number of subjects: 80
Study 28645949 — intervention group
Group type: EXPERIMENTAL
Intervention: S. maxima plus exercise
Number of subjects: 80
Study 28645949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 80
Study 25253549 — intervention group
Group type: EXPERIMENTAL
Intervention: Real needle acupuncture on Zhubin (KI9)
Number of subjects: 20
Study 25253549 — intervention group
Group type: COMPARATOR
Intervention: Placebo needle acupuncture
Number of subjects: 20
Study 23769724 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-esteem group
Number of subjects: 30
Study 23769724 — intervention group
Group type: COMPARATOR
Intervention: High self-esteem group
Number of subjects: 30
Study 21445287 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-enriched onion (50 µg/day)
Number of subjects: 119
Study 21445287 — intervention group
Group type: COMPARATOR
Intervention: 200 µg/day Se-enriched yeast
Number of subjects: 119
Study 21445287 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine challenge
Number of subjects: 119
Study 19419670 — intervention group
Group type: EXPERIMENTAL
Intervention: semi‐solid product
Number of subjects: 32
Study 19419670 — intervention group
Group type: COMPARATOR
Intervention: liquid product
Number of subjects: 32
Study 16414208 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 641
Study 16414208 — intervention group
Group type: COMPARATOR
Intervention: 78 Gy
Number of subjects: 641
Study 15276686 — intervention group
Group type: EXPERIMENTAL
Intervention: Average nicotine (AN) cigarettes
Number of subjects: 21
Study 15276686 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine (LN) cigarettes
Number of subjects: 21
Study 11509081 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg with each of 2-10 daily levodopa doses)
Number of subjects: 326
Study 11509081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 11509081 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 326
Study 11509081 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone withdrawal
Number of subjects: 326
Study 9243565 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual interview in the workplace
Number of subjects: 1200
Study 9243565 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-administered questionnaire in the workplace
Number of subjects: 1200
Study 9243565 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 1200
Study 9243565 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual interview off the worksite
Number of subjects: 1200
Study 9243565 — intervention group
Group type: COMPARATOR
Intervention: Urinalysis
Number of subjects: 1200
Study 9243565 — intervention group
Group type: COMPARATOR
Intervention: Hair analysis
Number of subjects: 1200
Study 8480685 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn/d, n = 65)
Number of subjects: 130
Study 8480685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 65)
Number of subjects: 130
Study 3527691 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 33
Study 3527691 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety reduction intervention
Number of subjects: 33
Study 3527691 — intervention group
Group type: COMPARATOR
Intervention: Information group (control)
Number of subjects: 33
Study 31686577 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation training (AOT)
Number of subjects: 87
Study 31686577 — intervention group
Group type: COMPARATOR
Intervention: Control training (C)
Number of subjects: 87
Study 31745964 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-Assisted Learning (PAL)
Number of subjects: 40
Study 30097067 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline malate (CM) 8 g (1.11:1 ratio)
Number of subjects: 0
Study 30097067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30097067 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline malate (CM)
Number of subjects: 0
Study 26834211 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab IV loading 10 mg/kg at baseline, Weeks 2 and 4, then SC 150 mg every 4 weeks (n = 88)
Number of subjects: 221
Study 26834211 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab SC loading 150 mg once weekly for 5 weeks, then every 4 weeks (n = 89)
Number of subjects: 221
Study 26834211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 221
Study 26834211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled secukinumab
Number of subjects: 221
Study 26834211 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab and placebo
Number of subjects: 221
Study 24145221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone augmentation of clozapine
Number of subjects: 40
Study 22176998 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of medical treatment with β-blockers and angiotensin-converting enzyme inhibitors
Number of subjects: 503
Study 22176998 — intervention group
Group type: COMPARATOR
Intervention: No optimization of medical treatment (baseline 'SCD-HeFT criteria' not met)
Number of subjects: 503
Study 22176998 — intervention group
Group type: COMPARATOR
Intervention: Group A1 (patients who maintained 'SCD-HeFT criteria')
Number of subjects: 503
Study 22176998 — intervention group
Group type: COMPARATOR
Intervention: Group A2 (patients who improved)
Number of subjects: 503
Study 22176998 — intervention group
Group type: COMPARATOR
Intervention: Group B1 (patients who developed 'SCD-HeFT criteria')
Number of subjects: 503
Study 22176998 — intervention group
Group type: COMPARATOR
Intervention: Group B2 (patients who remained without 'SCD-HeFT criteria')
Number of subjects: 503
Study 21519359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU daily)
Number of subjects: 63
Study 21519359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 18318568 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg administered as a 15-minute infusion every 3-4 weeks
Number of subjects: 0
Study 18318568 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 0
Study 18318568 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid therapy
Number of subjects: 0
Study 16278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 48
Study 16278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 48
Study 16278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil plus testosterone
Number of subjects: 48
Study 16278367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12709719 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 800 mg
Number of subjects: 0
Study 12709719 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 1000 mg
Number of subjects: 0
Study 12709719 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 1500 mg
Number of subjects: 0
Study 12709719 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 10898688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4) at doses of 1, 2, and 3 g
Number of subjects: 12
Study 10898688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10898688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4)
Number of subjects: 12
Study 8799404 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral dextrose (10 kcal/kg/day) for seven days following hepatectomy
Number of subjects: 19
Study 8799404 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic glucose
Number of subjects: 19
Study 1811970 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliance only
Number of subjects: 34
Study 1811970 — intervention group
Group type: COMPARATOR
Intervention: Intermaxillary wiring with subsequent functional therapy and/or functional appliances
Number of subjects: 34
Study 6347747 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of quazepam
Number of subjects: 60
Study 6347747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30950694 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional shifting task with varying demands (low, medium, high load)
Number of subjects: 50
Study 30950694 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional shifting task with high attentional load
Number of subjects: 50
Study 30950694 — intervention group
Group type: COMPARATOR
Intervention: Attentional shifting task (nonshifting trials)
Number of subjects: 50
Study 27077996 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol introduction with education and 3-month interim review
Number of subjects: 264
Study 27077996 — intervention group
Group type: COMPARATOR
Intervention: Protocol introduction alone
Number of subjects: 264
Study 27077996 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol introduction with education
Number of subjects: 264
Study 25332355 — intervention group
Group type: EXPERIMENTAL
Intervention: Four reminders
Number of subjects: 283
Study 25332355 — intervention group
Group type: EXPERIMENTAL
Intervention: ¥5.0 credit reward for replying
Number of subjects: 283
Study 25332355 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback text message
Number of subjects: 283
Study 25332355 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 283
Study 24727262 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 607
Study 24727262 — intervention group
Group type: COMPARATOR
Intervention: Topical medications
Number of subjects: 607
Study 24727262 — intervention group
Group type: EXPERIMENTAL
Intervention: Better intraocular pressure (IOP) control
Number of subjects: 607
Study 24727262 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 607
Study 24727262 — intervention group
Group type: EXPERIMENTAL
Intervention: Visits 1 year prior to cataract extraction
Number of subjects: 607
Study 24727262 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between treatment and baseline MD
Number of subjects: 607
Study 23043563 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based screening with a threshold of ≥ 3.0 ng/mL
Number of subjects: 42376
Study 23043563 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based screening
Number of subjects: 42376
Study 23043563 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat biopsies
Number of subjects: 42376
Study 19543123 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Advantage (MA)
Number of subjects: 390756
Study 19543123 — intervention group
Group type: COMPARATOR
Intervention: Traditional fee-for-service (FFS) Medicare
Number of subjects: 390756
Study 19543123 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive services in MA
Number of subjects: 390756
Study 19543123 — intervention group
Group type: COMPARATOR
Intervention: Preventive services in FFS
Number of subjects: 390756
Study 19543123 — intervention group
Group type: EXPERIMENTAL
Intervention: Office wait time and immunization rates in MA
Number of subjects: 390756
Study 17518105 — intervention group
Group type: EXPERIMENTAL
Intervention: Form priming with related primes and targets (e.g., lou3 'hug'‐‐lou2 'hall')
Number of subjects: 0
Study 17518105 — intervention group
Group type: EXPERIMENTAL
Intervention: Form priming with unrelated primes and targets (e.g., lou3 'hug'‐‐jian4zhu0 'building')
Number of subjects: 0
Study 15065478 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase group (maintained EMG activity above 10 microV)
Number of subjects: 14
Study 15065478 — intervention group
Group type: COMPARATOR
Intervention: Decrease group (maintained EMG activity below 2 microV)
Number of subjects: 14
Study 11785593 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (0.5 mg IV)
Number of subjects: 40
Study 11785593 — intervention group
Group type: COMPARATOR
Intervention: Morphine (5 mg IV)
Number of subjects: 40
Study 9737475 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0
Study 9737475 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 0
Study 9737475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7921469 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 5662
Study 7921469 — intervention group
Group type: EXPERIMENTAL
Intervention: PC20FEV1 < or = 5 mg/ml (AHR5)
Number of subjects: 5662
Study 7921469 — intervention group
Group type: EXPERIMENTAL
Intervention: PC20FEV1 < or = 25 mg/ml (AHR25)
Number of subjects: 5662
Study 3268274 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference group instructions (age group peers)
Number of subjects: 0
Study 3268274 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference group instructions (adults in general)
Number of subjects: 0
Study 3268274 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference group instructions (themselves at a younger age)
Number of subjects: 0
Study 3268274 — intervention group
Group type: COMPARATOR
Intervention: No instructions (standard instructional format)
Number of subjects: 0
Study 31034347 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin composite (PA: Peak Universal+Amelogen Plus, Ultradent)
Number of subjects: 53
Study 31034347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-shrinkage flowable and nanoparticulate resin composites (ABF: Adper Single Bond 2+Filtek Bulk Fill Flow+Filtek Z350XT, 3M ESPE)
Number of subjects: 53
Study 31034347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-shrinkage flowable and microhybrid resin composites (XST: XP Bond+SDR+TPH3, Dentsply)
Number of subjects: 53
Study 30476361 — intervention group
Group type: EXPERIMENTAL
Intervention: Samidorphan (10 mg)
Number of subjects: 47
Study 30476361 — intervention group
Group type: EXPERIMENTAL
Intervention: Samidorphan (30 mg)
Number of subjects: 47
Study 30476361 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (40 mg)
Number of subjects: 47
Study 30476361 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (30 mg)
Number of subjects: 47
Study 30476361 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (100 mg)
Number of subjects: 47
Study 30476361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28117843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (serum level 0.6 mmol l-1, n=20)
Number of subjects: 26
Study 28117843 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (flexibly dosed up to 800 mg per day, n=19)
Number of subjects: 26
Study 28117843 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=20)
Number of subjects: 26
Study 26467791 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 41
Study 26467791 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol dissolvable chewable tablets
Number of subjects: 41
Study 26467791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no xylitol)
Number of subjects: 41
Study 23230135 — intervention group
Group type: EXPERIMENTAL
Intervention: AIB1 in systemically untreated women
Number of subjects: 490
Study 23230135 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen treatment in pre- and postmenopausal women
Number of subjects: 490
Study 23230135 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX2 in ER-positive patients receiving tamoxifen
Number of subjects: 490
Study 21630176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative home exercise sensorimotor training programme
Number of subjects: 80
Study 21630176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 80
Study 18054209 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine plus pindolol (2.5 mg t.i.d.)
Number of subjects: 50
Study 18054209 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine plus placebo
Number of subjects: 50
Study 17006066 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with lower tidal volumes (6 ml/kg) and 10 cm H2O PEEP
Number of subjects: 40
Study 17006066 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation with higher tidal volumes (12 ml/kg) and no PEEP
Number of subjects: 40
Study 14621239 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (11%, 13%, 16%, 21%)
Number of subjects: 180
Study 14621239 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (16%, 21%)
Number of subjects: 180
Study 14621239 — intervention group
Group type: COMPARATOR
Intervention: Control solutions (tap water, Carbopol, Carbopol-urea)
Number of subjects: 180
Study 10811092 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin A ophthalmic emulsion 0.05%
Number of subjects: 162
Study 10811092 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin A ophthalmic emulsion 0.1%
Number of subjects: 162
Study 10811092 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 162
Study 8644961 — intervention group
Group type: EXPERIMENTAL
Intervention: No hyperbaric oxygen therapy (HBO)
Number of subjects: 4
Study 1397669 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Vi CPS vaccine
Number of subjects: 637
Study 1397669 — intervention group
Group type: COMPARATOR
Intervention: Heat‐killed whole‐cell typhoid vaccine
Number of subjects: 637
Study 3932051 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 micrograms, q.i.d.
Number of subjects: 703
Study 3932051 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms, q.i.d.
Number of subjects: 703
Study 3932051 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg, q.i.d.
Number of subjects: 703
Study 30712740 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training for 8 weeks
Number of subjects: 64
Study 30712740 — intervention group
Group type: COMPARATOR
Intervention: Control group (passive control)
Number of subjects: 64
Study 28287800 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (MI)
Number of subjects: 167
Study 28287800 — intervention group
Group type: COMPARATOR
Intervention: Time- and attention-matched control of meditation and relaxation training
Number of subjects: 167
Study 25887086 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 889
Study 25887086 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10
Number of subjects: 889
Study 25887086 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 889
Study 25887086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed PCV10 + PCV13 schedule
Number of subjects: 889
Study 24853094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 20,000 IU/week
Number of subjects: 90
Study 24853094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 40,000 IU/week
Number of subjects: 90
Study 24853094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22417930 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT stimulus at 900 mA
Number of subjects: 18
Study 22417930 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT stimulus at 1150 mA
Number of subjects: 18
Study 20008701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 1346